Toward an understanding of tissue factor pathway inhibitor‐2 as a novel serodiagnostic marker for clear cell carcinoma of the ovary

2021 ◽  
Author(s):  
Hiroshi Kobayashi ◽  
Shogo Imanaka
Keyword(s):  
Cell Carcinoma ◽  
Tissue Factor ◽  
Tissue Factor Pathway Inhibitor ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Tissue Factor Pathway ◽  
Carcinoma Of The Ovary

scholarly journals Tissue factor pathway inhibitor‑2 is specifically expressed in ovarian clear cell carcinoma tissues in the nucleus, cytoplasm and extracellular matrix

2021 ◽  
Vol 45 (3) ◽  
pp. 1023-1032
Author(s):  
Yukihide Ota ◽  
Shiro Koizume ◽  
Yoshiyasu Nakamura ◽  
Mitsuyo Yoshihara ◽  
Tomoko Takahashi ◽  
...  
Keyword(s):  
Extracellular Matrix ◽  
Cell Carcinoma ◽  
Tissue Factor ◽  
Tissue Factor Pathway Inhibitor ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Ovarian Clear Cell Carcinoma ◽  
Tissue Factor Pathway

scholarly journals Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma

PLoS ONE ◽  
2016 ◽  
Vol 11 (10) ◽  
pp. e0165609 ◽  
Author(s):  
Noriaki Arakawa ◽  
Hiroshi Kobayashi ◽  
Naohiro Yonemoto ◽  
Yusuke Masuishi ◽  
Yoko Ino ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Tissue Factor ◽  
Clinical Significance ◽  
Tissue Factor Pathway Inhibitor ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Serum Biomarker ◽  
Ovarian Clear Cell Carcinoma ◽  
Tissue Factor Pathway

scholarly journals Validation of tissue factor pathway inhibitor 2 as a specific biomarker for preoperative prediction of clear cell carcinoma of the ovary

2021 ◽  
Author(s):  
Etsuko Miyagi ◽  
Noriaki Arakawa ◽  
Kentaro Sakamaki ◽  
Naho Ruiz Yokota ◽  
Takeharu Yamanaka ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Tissue Factor ◽  
Tissue Factor Pathway Inhibitor ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Benign Lesions ◽  
Cancer Antigen 125 ◽  
Serum Samples ◽  
Ovarian Endometriosis ◽  
Tissue Factor Pathway

Abstract Background Tissue factor pathway inhibitor 2 (TFPI2) is a novel serum biomarker that discriminates ovarian clear cell carcinoma (CCC) from borderline ovarian tumors (BOTs) and non-clear cell epithelial ovarian cancers (EOCs). Here, we examined the performance of TFPI2 for preoperative diagnosis of CCC. Methods Serum samples were obtained preoperatively from patients with ovarian masses, who needed surgical treatment at five hospitals in Japan. The diagnostic powers of TFPI2 and cancer antigen 125 (CA125) serum levels to discriminate CCC from BOTs, other EOCs, and benign lesions were compared. Results A total of 351 patients including 69 CCCs were analyzed. Serum TFPI2 levels were significantly higher in CCC patients (mean ± SD, 508.2 ± 812.0 pg/mL) than in patients with benign lesions (154.7 ± 46.5), BOTs (181 ± 95.5) and other EOCs (265.4 ± 289.1). TFPI2 had a high diagnostic specificity for CCC (79.5%). In patients with benign ovarian endometriosis, no patient was positive for TFPI2, but 71.4% (15/21) were CA125 positive. TFPI2 showed good performance in discriminating stage II–IV CCC from BOTs and other EOCs (AUC 0.815 for TFPI2 versus 0.505 for CA125) or endometriosis (AUC 0.957 for TFPI2 versus 0.748 for CA125). The diagnostic sensitivity of TFPI2 to discriminate CCC from BOTs and other EOCs was improved from 43.5 to 71.0% when combined with CA125. Conclusions High specificity of TFPI2 for preoperative detection of CCC was verified with the defined cutoff level of TFPI2 in clinical practice. TFPI2 and CA125 may contribute substantially to precise prediction of intractable CCC.

Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes

2021 ◽  
Author(s):  
Angiolo Gadducci ◽  
Francesco Multinu ◽  
Stefania Cosio ◽  
Silvestro Carinelli ◽  
Mariacristina Ghioni ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clinical Outcomes ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Treatment Options ◽  
Biological Features ◽  
Carcinoma Of The Ovary

scholarly journals Ruptured clear cell carcinoma of the ovary presenting as acute abdomen

2016 ◽  
Vol 16 ◽  
pp. 1-4
Author(s):  
Zhen Ni Zhou ◽  
Christina Tierney ◽  
William H. Rodgers ◽  
Long Nguyen ◽  
David Fishman
Keyword(s):  
Cell Carcinoma ◽  
Acute Abdomen ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Carcinoma Of The Ovary

scholarly journals Are platinum agents, paclitaxel and irinotecan effective for clear cell carcinoma of the ovary? DNA damage detected with γH2AX induced by anticancer agents

2012 ◽  
Vol 5 (1) ◽  
pp. 16 ◽  
Author(s):  
Eriko Takatori ◽  
Tadahiro Shoji ◽  
Seisuke Kumagai ◽  
Takashi Sawai ◽  
Akira Kurose ◽  
...  
Keyword(s):  
Dna Damage ◽  
Cell Carcinoma ◽  
Anticancer Agents ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Carcinoma Of The Ovary ◽  
Platinum Agents

Clear cell carcinoma of the ovary: A review of the literature

2012 ◽  
Vol 126 (3) ◽  
pp. 481-490 ◽  
Author(s):  
Marcela G. del Carmen ◽  
Michael Birrer ◽  
John O. Schorge
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Review Of The Literature ◽  
Carcinoma Of The Ovary
Sign in / Sign up

Export Citation Format

Share Document